Report Overview

The EU Hemophilia A Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Hemophilia A is an X chromosome-linked genetic disorder caused by the mutations in the genes for factor VIII. This clotting factor is a part of the intrinsic pathway of blood coagulation. Without enough factor VIII, the blood cannot clot properly to control bleeding. It is mainly a defect in the gene on chromosome X, females have two copies of the X chromosome. So, if the factor VIII gene on one chromosome does not work, the gene on the other chromosome can do the job of making enough factor VIII. On the other hand, males have only one X chromosome; if the factor VIII gene is missing on the male X chromosome, he will have hemophilia A that is why the most people with Hemophilia A are male



Market Drivers

The drivers carrying the market are in completion of clinical development and launch of these products in the market, might increase the market, and besides this, patients of Hemophilia A will have better management practices